After billion-dollar drug deal, patient death and trial hold cripple Mersana's shares
Just two years after inking a billion-dollar deal on its lead drug, Mersana’s cancer program has been put on a partial clinical hold by the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
